Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 438

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 438
---
340 
  
    Common stock issued for cash 
     247,126  
     -  
     2,361  
     -  
     -  
     2,361 
  
    Common stock and warrants issued for cash 
     3,898,852  
     4  
     25,424  
     -  
     -  
     25,428 
  
    Reclassification from redeemable common stock 
     75,697  
     -  
     799  
     -  
     -  
     799 
  
    Exercise of warrants for cash 
     108,000  
     -  
     422  
     -  
     -  
     422 
  
    Stock-based compensation 
     -  
     -  
     7,605  
     -  
     -  
     7,605 
  
    Gain on foreign currency translation 
     -  
     -  
     -  
     224  
     -  
     224 
  
    Net loss 
     -  
     -  
     -  
     -  
     (42,082) 
     (42,082)
  
    Balance as of December 31, 2024 
     22,280,451  
    $22  
    $195,754  
    $(575) 
    $(163,104) 
    $32,097 

See accompanying notes to these consolidated financial
statements.

F-5

INMUNE BIO INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

(In thousands)

    2024  
    2023 
  
    CASH FLOWS FROM OPERATING ACTIVITIES: 

    Net loss 
    $(42,082) 
    $(30,008)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Stock-based compensation 
     7,605  
     7,368 
  
    Accretion of debt discount 
     79  
     224 
  
    Changes in operating assets and liabilities: 

    Research and development tax credit rece